丙型肝炎相关肝癌患者来源异种移植瘤模型的建立及伊马替尼疗效评估
本研究从丙型肝炎相关肝细胞癌患者手术切除的肿瘤组织植入高度免疫缺陷小鼠,成功建立可传代的患者来源异种移植瘤(PDX)模型。该模型组织学与患者原发肿瘤相似,短串联重复序列分析证实来源于临床标本,且传代后HCV RNA不可检出。伊马替尼治疗可显著抑制PDX肿瘤生长并降低磷酸化Akt和cyclin D1表达。
要点
- 成功建立HCV相关肝细胞癌PDX模型并至少传代三轮
- PDX模型保留患者原发肿瘤组织学特征及c-Kit mRNA高表达
- 伊马替尼显著抑制PDX肿瘤生长并降低p-Akt和cyclin D1
核心结论
- 成功建立HCV相关肝细胞癌PDX模型,可作为评估候选药物的有力工具。
- 伊马替尼治疗显著抑制PDX肿瘤生长并降低磷酸化Akt和cyclin D1表达。
研究设计与样本
- 将HCV相关肝细胞癌患者手术切除的肿瘤组织植入高度免疫缺陷小鼠。
- 建立小鼠异种移植瘤系并在免疫缺陷小鼠中成功传代至少三轮。
主要发现
- 患者原发肿瘤与小鼠异种移植瘤组织学相似。
- 短串联重复序列分析证实PDX模型来源于肝癌临床标本。
- 患者肝脏标本中的HCV RNA在传代为小鼠异种移植瘤后不可检出。
- 人白蛋白、α1-抗胰蛋白酶、glypican-3、α-平滑肌肌动蛋白和1A2型胶原标志物在原始肿瘤和异种移植瘤中均可检出。
- 患者原发肿瘤和异种移植瘤的受体酪氨酸激酶c-Kit mRNA水平均显著升高。
临床怎么用
- 该PDX模型可用于筛选和评估针对HCV相关肝细胞癌的候选药物。
- 肿瘤特异性基因表达分子变化信息有助于制定高效靶向治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Chronic hepatitis C virus (HCV) infection is one of the major causal factors for hepatocellular carcinoma (HCC). The treatment options for HCC are limited for lack of a convenient animal model for study in HCV infection and liver pathogenesis. This study aimed to develop a patient-derived xenograft (PDX) tumor in mice by using a tumor from a patient with HCV-associated HCC and evaluating this model's therapeutic potential. APPROACH AND RESULTS: After resection of the primary tumor from the patient liver, excess viable tumor was implanted into highly immunodeficient mice. A mouse xenograft tumor line was developed, and the tumor was successfully passaged for at least three rounds in immunodeficient mice. The patient's primary tumor and the mouse xenografts were histologically similar. Genetic profiling by short-tandem-repeat analysis verified that the HCC-PDX model was derived from the HCC clinical specimen. HCV RNA present in the patient liver specimen was undetectable after passage as xenograft tumors in mice. Human albumin, α1 -antitrypsin, glypican-3, α-smooth muscle actin, and collagen type 1A2 markers were detected in human original tumor tissues and xenograft tumors. Both the patient primary tumor and the xenograft tumors had a significantly higher level of receptor tyrosine kinase (c-Kit) mRNA. Treatment of HCC-PDX xenograft tumor-bearing mice with the c-Kit inhibitor imatinib significantly reduced tumor growth and phospho-Akt and cyclin D1 expression, as compared with untreated control tumors. CONCLUSIONS: Our results demonstrated establishment of an HCV-associated HCC-PDX model as a powerful tool for evaluating candidate drugs. Information on molecular changes in cancer-specific gene expression facilitates efficient targeted therapies and treatment strategies.
引用
- Nazzal M, Sur S, Steele R, et al. Establishment of a Patient-Derived Xenograft Tumor From Hepatitis C-Associated Liver Cancer and Evaluation of Imatinib Treatment Efficacy. Hepatology. 2020. PMID: 32356575. doi:10.1002/hep.31298
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。